What specifically changed in the LRMR analyst rating on March 03, 2026?

Wedbush maintained an **Outperform** rating on March 03, 2026 and raised its **price target to $12**. The note reflected updated model inputs and milestones. The market moved **1.85%**, or **$0.10**, on the update.

How should investors interpret the LRMR analyst rating from Wedbush?

A maintained Outperform indicates continued confidence rather than a new directional call. The raised **$12 price target** sets an upside benchmark. Investors should compare the target to company catalysts and cash runway.

Does the LRMR analyst rating affect stock price immediately?

Yes. Analyst notes often trigger near-term moves in mid-cap biotechs. LRMR rose **1.85%** on the Wedbush note. Longevity of the move depends on company news and follow-up coverage.

Where can I read the full Wedbush note on LRMR analyst rating?

The Wedbush update is summarized on StreetInsider. Read the coverage here: [StreetInsider coverage](https://www.streetinsider.com/Analyst+Comments/Larimar+Therapeutics+%28LRMR%29+PT+Raised+to+%2412+at+Wedbush/26098049.html).

Analyst Ratings

Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026

ByHuzaifa Zahoor March 4, 2026

On March 03, 2026 Wedbush maintained an Outperform rating on Larimar Therapeutics, Inc. (LRMR) and raised its price target to $12. The LRMR analyst rating update keeps Wedbush aligned with a growth view while the market reacted with a 1.85% move, or $0.10. This note is notable because Wedbush is a recognized life sciences desk and its view can influence trading in thinly covered biotechs. We summarize the rating action, the new price target, and what investors should weigh now.